Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride Gas for Submacular Haemorrhage Displacement in Age-Related Macular Degeneration: Looking behind the Blood

Ophthalmologica. 2020;243(3):224-235. doi: 10.1159/000505752. Epub 2020 Jan 7.

Abstract

Purpose: To evaluate the effectiveness of recombinant tissue plasminogen activator (rtPA) and sulphur hexafluoride gas (SF6) intravitreal injection for the displacement of large submacular haemorrhages (SMH) secondary to neovascular age-related macular degeneration and for guiding the selection of additional treatments or observations for choroidal neovascularization (CNV).

Methods: The medical records of consecutive patients with recent-onset, large SMH, treated at Sacro Cuore Hospital from January 2004 to May 2016, were retrospectively analysed. All eyes underwent a 0.05-mL intravitreal injection of 50 μg rtPA, 0.3 mL of 100% SF6, and then face-down positioning. Afterwards, the eyes received additional treatments for CNV or observation, based on the severity and extent of the underlying pathology. The multimodal imaging features revealed after blood displacement were analysed and then correlated to the treatment selected as a second therapeutic option.

Results: A total of 96 eyes met the inclusion criteria and was evaluated in this study. SMH was displaced from the fovea in the majority of the eyes (76%), allowing several diagnostic tools to evaluate the underlying macular features. In 19 cases (19.8%) exhibiting severe macular damage, no additional treatment was applied. In the remaining eyes, subsequent treatments included anti-vascular endothelial growth factor injections (44.8%), photodynamic therapy (n = 2), and submacular surgery (35.4%). Statistically significant correlations were found between the macular findings revealed after blood displacement and the additional treatments or observations selected for the underlying disease. The mean follow-up was 35 months. Improvements in visual acuity were statistically significant up to 3 years.

Conclusion: Intravitreal rtPA and gas injection was found to be effective for the displacement of large SMH, allowing postoperative diagnostic testing, and thus guiding the opportunity to apply further treatments. The addition of subsequent individualized treatments may allow long-term visual gain in selected cases.

Keywords: Age-related macular degeneration; Gas displacement; Recombinant tissue plasminogen activator; Submacular haemorrhage; Sulphur hexafluoride.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Choroidal Neovascularization / complications*
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / physiopathology
  • Combined Modality Therapy
  • Endotamponade*
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Male
  • Middle Aged
  • Prone Position
  • Recombinant Proteins / administration & dosage
  • Retinal Hemorrhage / etiology
  • Retinal Hemorrhage / physiopathology
  • Retinal Hemorrhage / therapy*
  • Retrospective Studies
  • Sulfur Hexafluoride / administration & dosage*
  • Tissue Plasminogen Activator / administration & dosage*
  • Tomography, Optical Coherence
  • Visual Acuity / physiology
  • Vitrectomy
  • Wet Macular Degeneration / complications*
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / physiopathology

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator
  • Sulfur Hexafluoride